J&J's Myasthenia Gravis Drug Approved in China; Kelun-Biotech's TROP2 ADC Hits Primary Endpoint in Phase III TNBC Trial
May 21, 2026 19:49
CST Updated
May 22, 02:49
Johnson & Johnson
Medical Device R&D and Manufacturer
Kelun-Biotech
Innovative Drug Developer
Junshi Biosciences
Innovative Drug Developer
CHIATAI TIANQING
High-quality pharmaceuticals research, production, and sales provider